Sabra Health Care REIT Analyst Ratings
Sabra Health Care REIT Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
08/11/2023 | 12.63% | B of A Securities | $11 → $14 | Upgrades | Underperform → Neutral |
07/27/2023 | 4.59% | Berenberg | → $13 | Initiates Coverage On | → Hold |
07/14/2023 | 0.56% | Citigroup | $11 → $12.5 | Maintains | Neutral |
04/25/2023 | 4.59% | Barclays | $15 → $13 | Maintains | Equal-Weight |
04/20/2023 | -11.5% | Wells Fargo | → $11 | Initiates Coverage On | → Underweight |
04/19/2023 | -11.5% | Wells Fargo | → $11 | Initiates Coverage On | → Underweight |
04/12/2023 | 4.59% | Credit Suisse | → $13 | Reiterates | → Neutral |
03/29/2023 | 4.59% | Truist Securities | $14 → $13 | Maintains | Buy |
03/28/2023 | -15.53% | Citigroup | $13 → $10.5 | Maintains | Neutral |
12/13/2022 | — | JMP Securities | Downgrades | Market Outperform → Market Perform | |
11/14/2022 | 4.59% | B of A Securities | $15 → $13 | Downgrades | Neutral → Underperform |
10/10/2022 | 4.59% | Baird | → $13 | Downgrades | Outperform → Neutral |
06/30/2022 | 12.63% | Jefferies | $15 → $14 | Downgrades | Buy → Hold |
05/25/2022 | 20.68% | Mizuho | $16 → $15 | Upgrades | Neutral → Buy |
04/18/2022 | 12.63% | Barclays | $16 → $14 | Downgrades | Overweight → Equal-Weight |
04/04/2022 | 20.68% | Credit Suisse | $14 → $15 | Maintains | Neutral |
03/11/2022 | 20.68% | B of A Securities | → $15 | Upgrades | Underperform → Neutral |
02/23/2022 | 44.81% | Stifel | $21 → $18 | Maintains | Buy |
02/18/2022 | — | Keybanc | Initiates Coverage On | → Sector Weight | |
02/01/2022 | 12.63% | Credit Suisse | → $14 | Initiates Coverage On | → Neutral |
09/30/2021 | 44.81% | Truist Securities | → $18 | Upgrades | Hold → Buy |
09/13/2021 | 60.9% | JMP Securities | $24 → $20 | Maintains | Market Outperform |
05/21/2021 | 68.95% | BMO Capital | $20 → $21 | Upgrades | Market Perform → Outperform |
05/10/2021 | 68.95% | Stifel | $17 → $21 | Upgrades | Hold → Buy |
01/13/2021 | 60.9% | Jefferies | $17 → $20 | Upgrades | Hold → Buy |
01/08/2021 | 52.86% | BMO Capital | → $19 | Upgrades | Underperform → Market Perform |
12/03/2020 | 93.08% | JMP Securities | → $24 | Upgrades | Market Perform → Market Outperform |
09/02/2020 | 20.68% | Stifel | → $15 | Reinstates | → Hold |
06/23/2020 | 20.68% | Scotiabank | $12 → $15 | Upgrades | Sector Underperform → Sector Perform |
06/22/2020 | 12.63% | Wells Fargo | $13 → $14 | Maintains | Equal-Weight |
05/18/2020 | 20.68% | Berenberg | → $15 | Upgrades | Hold → Buy |
04/23/2020 | — | SunTrust Robinson Humphrey | Maintains | Hold | |
04/07/2020 | -19.55% | Citigroup | $20 → $10 | Maintains | Neutral |
03/26/2020 | -15.53% | Wells Fargo | $22 → $10.5 | Maintains | Equal-Weight |
02/26/2020 | 76.99% | Mizuho | → $22 | Upgrades | Neutral → Buy |
02/06/2020 | 101.13% | Barclays | $26 → $25 | Maintains | Overweight |
02/05/2020 | 76.99% | Berenberg | → $22 | Initiates Coverage On | → Hold |
12/20/2019 | 76.99% | Mizuho | → $22 | Initiates Coverage On | → Neutral |
12/18/2019 | — | Citigroup | Upgrades | Sell → Neutral | |
10/14/2019 | — | B of A Securities | Reinstates | → Neutral | |
09/27/2019 | 85.04% | JMP Securities | $22 → $23 | Maintains | Market Outperform |
09/23/2019 | 60.9% | Citigroup | $18 → $20 | Downgrades | Neutral → Sell |
09/03/2019 | 93.08% | Barclays | → $24 | Initiates Coverage On | → Overweight |
02/26/2019 | — | BMO Capital | Downgrades | Market Perform → Underperform | |
12/17/2018 | 52.86% | Wells Fargo | $23 → $19 | Maintains | Market Perform |
11/16/2018 | 68.95% | B of A Securities | $23 → $21 | Downgrades | Neutral → Underperform |
11/16/2018 | — | Raymond James | Downgrades | Outperform → Market Perform | |
11/13/2018 | 68.95% | Mizuho | → $21 | Downgrades | Buy → Neutral |
09/19/2018 | 93.08% | BMO Capital | → $24 | Initiates Coverage On | → Market Perform |
08/17/2018 | 93.08% | Raymond James | $22 → $24 | Maintains | Outperform |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
08/11/2023 | 12.63% | B of A 类证券 | 11 美元 → 14 美元 | 升级 | 表现不佳 → 中性 |
07/27/2023 | 4.59% | 贝伦贝格 | → 13 美元 | 启动覆盖开启 | → 按住 |
07/14/2023 | 0.56% | 花旗集团 | 11 美元 → 12.5 美元 | 维护 | 中立 |
2023 年 4 月 25 日 | 4.59% | 巴克莱 | 15 美元 → 13 美元 | 维护 | 重量相等 |
04/20/2023 | -11.5% | 富国银行 | → 11 美元 | 启动覆盖开启 | → 体重不足 |
04/19/2023 | -11.5% | 富国银行 | → 11 美元 | 启动覆盖开启 | → 体重不足 |
2023 年 12 月 4 日 | 4.59% | 瑞士信贷 | → 13 美元 | 重申 | → 中立 |
03/29/2023 | 4.59% | 信托证券 | 14 美元 → 13 美元 | 维护 | 购买 |
03/28/2023 | -15.53% | 花旗集团 | 13 美元 → 10.5 美元 | 维护 | 中立 |
12/13/2022 | — | JMP 证券 | 降级 | 市场跑赢大盘 → 市场表现 | |
11/14/2022 | 4.59% | B of A 类证券 | 15 美元 → 13 美元 | 降级 | 中性 → 跑赢大盘 |
2022 年 10 月 10 日 | 4.59% | 贝尔德 | → 13 美元 | 降级 | 跑赢大盘 → 中性 |
06/30/2022 | 12.63% | 杰富瑞 | 15 美元 → 14 美元 | 降级 | 买入 → 持有 |
05/25/2022 | 20.68% | 瑞穗 | 16 美元 → 15 美元 | 升级 | 中性 → 买入 |
04/18/2022 | 12.63% | 巴克莱 | 16 美元 → 14 美元 | 降级 | 超重 → 重量相等 |
2022 年 4 月 4 日 | 20.68% | 瑞士信贷 | 14 美元 → 15 美元 | 维护 | 中立 |
03/11/2022 | 20.68% | B of A 类证券 | → 15 美元 | 升级 | 表现不佳 → 中性 |
2022 年 2 月 23 日 | 44.81% | Stifel | 21 美元 → 18 美元 | 维护 | 购买 |
2022 年 2 月 18 日 | — | Keybanc | 启动覆盖开启 | → 行业权重 | |
2022 年 1 月 2 日 | 12.63% | 瑞士信贷 | → 14 美元 | 启动覆盖开启 | → 中立 |
09/30/2021 | 44.81% | 信托证券 | → 18 美元 | 升级 | 持有 → 买入 |
09/13/2021 | 60.9% | JMP 证券 | 24 美元 → 20 美元 | 维护 | 市场表现跑赢大盘 |
05/21/2021 | 68.95% | BMO 资本 | 20 美元 → 21 美元 | 升级 | 市场表现 → 跑赢大盘 |
2021 年 10 月 5 日 | 68.95% | Stifel | 17 美元 → 21 美元 | 升级 | 持有 → 买入 |
2021 年 1 月 13 日 | 60.9% | 杰富瑞 | 17 美元 → 20 美元 | 升级 | 持有 → 买入 |
01/08/2021 | 52.86% | BMO 资本 | → 19 美元 | 升级 | 表现不佳 → 市场表现 |
2020 年 3 月 12 日 | 93.08% | JMP 证券 | → 24 美元 | 升级 | 市场表现 → 市场跑赢大盘 |
2020 年 2 月 9 日 | 20.68% | Stifel | → 15 美元 | 恢复 | → 按住 |
06/23/2020 | 20.68% | 丰业银行 | 12 美元 → 15 美元 | 升级 | 板块表现不佳 → 板块表现 |
2020 年 6 月 22 日 | 12.63% | 富国银行 | 13 美元 → 14 美元 | 维护 | 重量相等 |
2020 年 5 月 18 日 | 20.68% | 贝伦贝格 | → 15 美元 | 升级 | 持有 → 买入 |
04/23/2020 | — | SunTrust 罗宾逊汉弗莱 | 维护 | 保持 | |
2020 年 7 月 4 日 | -19.55% | 花旗集团 | 20 美元 → 10 美元 | 维护 | 中立 |
2020 年 3 月 26 日 | -15.53% | 富国银行 | 22 美元 → 10.5 美元 | 维护 | 重量相等 |
02/26/2020 | 76.99% | 瑞穗 | → 22 美元 | 升级 | 中性 → 买入 |
02/06/2020 | 101.13% | 巴克莱 | 26 美元 → 25 美元 | 维护 | 超重 |
02/05/2020 | 76.99% | 贝伦贝格 | → 22 美元 | 启动覆盖开启 | → 按住 |
12/20/2019 | 76.99% | 瑞穗 | → 22 美元 | 启动覆盖开启 | → 中立 |
2019 年 12 月 18 日 | — | 花旗集团 | 升级 | 卖出 → 中立 | |
2019 年 10 月 14 日 | — | B of A 类证券 | 恢复 | → 中立 | |
09/27/2019 | 85.04% | JMP 证券 | 22 美元 → 23 美元 | 维护 | 市场表现跑赢大盘 |
2019 年 9 月 23 日 | 60.9% | 花旗集团 | 18 美元 → 20 美元 | 降级 | 中性 → 卖出 |
2019 年 3 月 9 日 | 93.08% | 巴克莱 | → 24 美元 | 启动覆盖开启 | → 超重 |
2019 年 2 月 26 日 | — | BMO 资本 | 降级 | 市场表现 → 跑赢大盘 | |
12/17/2018 | 52.86% | 富国银行 | 23 美元 → 19 美元 | 维护 | 市场表现 |
11/16/2018 | 68.95% | B of A 类证券 | 23 美元 → 21 美元 | 降级 | 中性 → 跑赢大盘 |
11/16/2018 | — | 雷蒙德·詹姆 | 降级 | 跑赢大盘 → 市场表现 | |
11/13/2018 | 68.95% | 瑞穗 | → 21 美元 | 降级 | 买入 → 中性 |
09/19/2018 | 93.08% | BMO 资本 | → 24 美元 | 启动覆盖开启 | → 市场表现 |
08/17/2018 | 93.08% | 雷蒙德·詹姆 | 22 美元 → 24 美元 | 维护 | 跑赢大盘 |
What is the target price for Sabra Health Care REIT (SBRA)?
Sabra Health Care REIT(SBRA)的目标价格是多少?
The latest price target for Sabra Health Care REIT (NASDAQ: SBRA) was reported by B of A Securities on August 11, 2023. The analyst firm set a price target for $14.00 expecting SBRA to rise to within 12 months (a possible 12.63% upside). 12 analyst firms have reported ratings in the last year.
A Securities于2023年8月11日公布了Sabra Health Care REIT(纳斯达克股票代码:SBRA)的最新目标股价。这家分析公司将目标股价定为14.00美元,预计SBRA将在12个月内升至12个月内(可能上涨12.63%)。去年有12家分析公司公布了评级。
What is the most recent analyst rating for Sabra Health Care REIT (SBRA)?
分析师对Sabra Health Care REIT(SBRA)的最新评级是多少?
The latest analyst rating for Sabra Health Care REIT (NASDAQ: SBRA) was provided by B of A Securities, and Sabra Health Care REIT upgraded their neutral rating.
Sabra Health Care REIT(纳斯达克股票代码:SBRA)的最新分析师评级由B of A Securities提供,Sabra Health Care REIT上调了中性评级。
When is the next analyst rating going to be posted or updated for Sabra Health Care REIT (SBRA)?
Sabra Health Care REIT(SBRA)的下一个分析师评级何时公布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sabra Health Care REIT, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sabra Health Care REIT was filed on August 11, 2023 so you should expect the next rating to be made available sometime around August 11, 2024.
分析师在进行了广泛的研究后得出了股票评级,其中包括浏览公开财务报表,与Sabra Health Care REIT的高管和客户交谈,以及听取财报电话会议。大多数分析师每三个月进行一次评级,因此每家公司每年应该获得4个评级。Sabra Health Care REIT的最后一次评级是在2023年8月11日提交的,因此您应该预计下一个评级将在2024年8月11日左右公布。
Is the Analyst Rating Sabra Health Care REIT (SBRA) correct?
分析师对Sabra Health Care REIT(SBRA)的评级正确吗?
While ratings are subjective and will change, the latest Sabra Health Care REIT (SBRA) rating was a upgraded with a price target of $11.00 to $14.00. The current price Sabra Health Care REIT (SBRA) is trading at is $12.43, which is within the analyst's predicted range.
尽管评级是主观的,将会发生变化,但最新的Sabra Health Care REIT(SBRA)评级已上调,目标股价为11.00美元至14.00美元。Sabra Health Care REIT(SBRA)目前的交易价格为12.43美元,在分析师的预测区间内。